Clinical trials: Hepatic Neoplasm
Liver Cancer
Liver Cancer HepaSphere Combined With Cryosurgery
The purpose of this study is to evaluate the safety and efficacy of HepaSphere interventional therapy using digital subtraction angiography（DSA）combined with cryosurgery for liver cancer.
- Trial name
- NCT02545556
- Testing
- HepaSphere combined with cryosurgery
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Intrahepatic Cholangiocarcinoma, Peripheral Cholangiocarcinoma
Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma
This is a Phase I study, which means we want to find out what effects, good and/or bad, this combination of drugs may have on the patient and the liver cancer at different dose levels.
- Conditions
- Intrahepatic Cholangiocarcinoma, Peripheral Cholangiocarcinoma, Cholangiolar Carcinoma, Cholangiocellular Carcinoma) (ICC)
- Trial name
- NCT01938729
- Testing
- Liver resection and placement of hepatic artery infusion pump, FLOXURIDINE, DEXAMETHASONE
- Where
- 5 sites in United States
- Volunteers
- 8 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatocellular Carcinoma
Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation
Percutaneous ablation (PA) is the only non-surgical curative treatment of hepatocellular carcinoma (HCC). Due to its excellent tolerance, particularly in patients with portal hypertension or bearing comorbidities, it now…
- Trial name
- NIVOLEP (NCT03630640)
- Testing
- Nivolumab Injection [Opdivo]
- Where
- France
- Volunteers
- 43 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatocellular Carcinoma, Radiotherapy
Combination of SFRT, PD-L1 Inhibitor, and Anti-VEGF in Advanced Hepatocellular Carcinoma
PD-1 inhibitor plus anti-VEGFR has become the established standard first-line systemic treatment for unresectable hepatocellular carcinoma (HCC).
- Conditions
- Hepatocellular Carcinoma, Radiotherapy, PD-1 Inhibitors
- Trial name
- NCT06708650
- Testing
- Combination of SFRT, PD-L1 inhibitor, and Anti-VEGF
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Guiping People's Hospital
Hepatocellular Carcinoma
A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma
This is a non-randomized, open-label, multi-site phase II therapeutic trial of pembrolizumab and bavituximab in patients with locally advanced HCC.
- Trial name
- NCT03519997
- Testing
- Pembrolizumab, Bavituximab
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- David Hsieh
Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment
To assess the impact of moderate hepatic impairment on cytarabine and daunorubicin pharmacokinetics and their metabolites following administration of CPX-351.
- Conditions
- Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS)
- Trial name
- NCT02269579
- Testing
- CPX-351
- Where
- 5 sites in United States
- Sponsor
- Jazz Pharmaceuticals
Hepatitis B, Chronic, Hepatocellular Carcinoma
PROLIFICA - West African Treatment Cohort for Hepatitis B
The West African Treatment Cohort for Hepatitis B (WATCH) study is a component of the European Commission Funded FP7 project PROLIFICA.
- Trial name
- WATCH (NCT02129829)
- Testing
- Tenofovir disoproxil
- Where
- 2 sites in Senegal, The Gambia
- Volunteers
- 1,079 people
- Sponsor
- Imperial College London
Hepatocellular Carcinoma
BioPearl™ Microspheres Loaded With Doxorubicin: Prospective, Single Arm, Multi-centre Post-market Follow-up Study.
The primary objective of the study is to confirm safety and efficacy of BioPearl™ microspheres loaded with doxorubicin in the treatment of patients with unresectable hepatocellular carcinoma (HCC).
- Trial name
- BIOPEARL-FIRST (NCT04231929)
- Testing
- Chemoembolization
- Where
- 3 sites in Belgium
- Sponsor
- Terumo Europe N.V.
Advanced Hepatocellular Carcinoma
GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma
The hepatocellular carcinoma (HCC) represents more than 5% of all human malignancies, with more than 500,000 deaths per year (1).
- Trial name
- SS-HCC (NCT00495846)
- Testing
- Octreotide-LAR, Lanreotide Autogel, Locoregional treatments
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Federico II University
Biliary Tract Neoplasms, Pancreatic Neoplasm
Portal Vein Stenting for Malignant Obstruction: Feasibility, Safety, and Clinical Outcomes
Introduction: Pre-hepatic portal hypertension of malignant origin can lead to severe complications such as refractory ascites or gastrointestinal bleeding, significantly impairing patients' quality of life.
- Conditions
- Biliary Tract Neoplasms, Pancreatic Neoplasm, Portal Hypertension, Portal Vein Thrombosis
- Trial name
- NCT07252570
- Testing
- Transhepatic portal vein stent implantation
- Where
- France
- Volunteers
- 63 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Carcinoma, Hepatocellular, Gastric/Gastroesophageal Junction Cancer
A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer
The purpose of this study was to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of sitravatinib as monotherapy and in combination with tislelizumab in participants with unresectable locally…
- Trial name
- NCT03941873
- Testing
- Sitravatinib, Tislelizumab
- Where
- 18 sites in China
- Volunteers
- 111 people
- Sponsor
- BeiGene
Hepatocellular Carcinoma (HCC)
A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
This Phase 3 study was a global, multicenter trial that randomly assigned participants to either tislelizumab or sorafenib as a first-line treatment for adults with advanced liver cancer (hepatocellular carcinoma) that could not…
- Trial name
- NCT03412773
- Testing
- Tislelizumab, Sorafenib
- Where
- 122 sites in United States, China and 9 more
- Volunteers
- 684 people
- Sponsor
- BeiGene
Liver Cancer, Hemorrhage Liver
Standard of Care Versus Hemopatch® During Liver Resection
This multicentre prospective and randomized study aims to compare the sealant effect after surgical liver resection of a new collagen - polyethylene glycol hemostatic / sealant patch (Hemopatch) vs standard of care.
- Conditions
- Liver Cancer, Hemorrhage Liver, Bile Leak, Surgery
- Trial name
- IBERLIVER (NCT03166683)
- Testing
- Hemopatch, Standard of care
- Volunteers
- 284 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Pancreatic Cancer
Correlation of Portal and Peripheral Venous ctDNA in Pancreatic Adenocarcinoma
This study aims to evaluate the prognostic impact of the detection of circulating tumor DNA in peripheral venous blood, portal venous blood, collected intraoperatively, as well as its detection in peritoneal fluid.
- Trial name
- VEINOPAN (NCT06478056)
- Testing
- pancreatectomy
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Rouen
Localized Non-Resectable Adult Liver Carcinoma
Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study
This research registry studies Yttrium Y 90 resin microspheres in collecting data from patients with liver cancer not capable of being removed by surgery (unresectable) for the radiation-emitting Selective Internal…
- Trial name
- RESiN (NCT02685631)
- Testing
- Yttrium-90 Resin Microspheres
- Where
- 42 sites in United States
- Volunteers
- 1,653 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Advanced Adult Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8
An Investigational Scan (Magnetic Resonance Elastography) in Detecting Treatment Response in Patients With Advanced Liver Cancer
This trial studies how well an investigational scan (magnetic resonance elastography [MRE]) works with standard imaging (magnetic resonance imaging [MRI]) in detecting response to treatment in patients with liver cancer that has…
- Conditions
- Advanced Adult Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT04022746
- Testing
- Magnetic Resonance Elastography, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Liver Neoplasms, Radiation-Induced Liver Injury
Radiotherapy Safety for Liver Malignancies Using Post-Treatment Imaging
The goal of this retrospective observational study is to investigate the safety of radiation therapy for liver malignancies by analyzing data from patients who have already completed this treatment .
- Trial name
- NCT07346573
- Testing
- Clinically Delivered Radiation Therapy (e.g., SBRT/IMRT) for Liver Cancer
- Where
- China
- Volunteers
- 274 people
- Sponsor
- Cao peiguo
Liver Cancer, Metastatic Liver Cancer
PDO/PDO-TIL/PDOTS for Drug Screen
This clinical trial aims to use the patient-derived organoid (PDO), Patient-derived organoids-tumor-infiltrating lymphocyte coculture system (PDO-TIL) and patient-derived organotypic tissue spheroids (PDOTS) to simulate the tumor…
- Trial name
- NCT05913141
- Testing
- Drug screen with PDO/PDO-TIL/PDOTS
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
An unmet medical need exists for the successful therapy of patients with advanced hepatocellular and biliary tract malignances, with few and short lived disease responses to chemotherapy for both advanced stage hepatic and…
- Trial name
- NCT00532441
- Testing
- Erlotinib, Docetaxel
- Where
- 12 sites in United States
- Volunteers
- 25 people
- Sponsor
- Gabi Chiorean, MD
Hepatocellular Carcinoma, COVID-19
COVID-19 Infection in Patients With Hepatocellular Carcinoma
Since December 2019, a new disease named COVID-19 linked to a new coronavirus, SARS-CoV2 has emerged in China in the city of Wuhan, Hubei province, spreading very quickly to all 5 continents, and responsible for a pandemic.
- Trial name
- COVID19-CHIEF (NCT04367805)
- Testing
- nasopharyngeal Covid 19 RT-PCR
- Where
- France
- Volunteers
- 23 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.